The global psoriasis treatment market is witnessing substantial growth as healthcare systems continue to prioritize effective management of chronic autoimmune diseases. Psoriasis affects millions of people worldwide and requires long-term treatment strategies to control symptoms, reduce inflammation, and improve patients' quality of life. Continuous advancements in immunology, dermatology research, and biologic drug development have significantly transformed the treatment landscape over the past decade. Healthcare providers are increasingly adopting targeted therapies that offer higher efficacy with fewer side effects compared to conventional systemic medications. Alongside biologics, oral small molecules, topical therapies, and combination treatment approaches continue to expand therapeutic options available to physicians and patients. Growing awareness campaigns, earlier diagnosis, favorable reimbursement policies, and increasing healthcare accessibility across developing countries are further contributing to sustained market expansion. As pharmaceutical companies continue investing heavily in clinical research and precision medicine, the psoriasis treatment market is expected to witness remarkable innovation throughout the forecast period.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=17960

Market Size and Growth

The global psoriasis treatment market was valued at US$ 35.0 billion in 2024 and is forecast to register a strong CAGR of 9.5% between 2025 and 2035, ultimately surpassing US$ 87.6 billion by the end of 2035. This impressive growth trajectory reflects the increasing global prevalence of psoriasis, rising diagnosis rates, expanding patient access to advanced therapies, and continuous product innovation. The introduction of highly effective biologics targeting specific inflammatory cytokines has revolutionized disease management, particularly among patients with moderate-to-severe psoriasis. Furthermore, expanding healthcare infrastructure in emerging economies, increasing insurance coverage, growing investments in specialty dermatology, and the launch of biosimilars are expected to make advanced treatment options more accessible over the coming years. Pharmaceutical companies are also focusing on improving treatment convenience through less frequent dosing schedules, oral formulations, and personalized therapeutic approaches, further supporting long-term market growth.

Market Segmentation

The psoriasis treatment market can be segmented by treatment type, route of administration, disease severity, distribution channel, and end user. Based on treatment type, the market includes biologics, topical therapies, systemic drugs, oral small molecules, and phototherapy. Biologic therapies continue to dominate revenue generation due to superior clinical outcomes and increasing physician preference for targeted immunomodulators. Topical treatments remain widely prescribed for patients with mild psoriasis, while oral therapies continue gaining popularity because of improved patient convenience and adherence. By disease severity, the market is categorized into mild, moderate, and severe psoriasis, with moderate-to-severe cases accounting for a significant share of biologic treatment demand. Distribution channels include hospital pharmacies, retail pharmacies, specialty pharmacies, and online pharmacies, each playing an increasingly important role in expanding patient access to advanced therapeutics. Hospitals and specialty dermatology clinics remain the primary treatment centers for complex psoriasis cases requiring biologic administration and continuous monitoring.

Regional Analysis

North America continues to lead the global psoriasis treatment market owing to high biologic adoption, advanced healthcare infrastructure, strong reimbursement systems, significant healthcare spending, and the presence of numerous leading pharmaceutical companies. The United States remains the largest contributor within the region due to extensive research activities and widespread availability of innovative therapies. Europe follows closely with strong market growth supported by universal healthcare systems, increasing awareness, favorable regulatory frameworks, and rising utilization of biologic medications. Germany, France, the United Kingdom, Italy, and Spain represent major regional contributors. Asia-Pacific is projected to record the fastest growth through 2035, driven by improving healthcare infrastructure, expanding patient populations, rising disposable incomes, increasing government healthcare investments, and greater access to innovative treatment options across China, India, Japan, South Korea, and Southeast Asia. Latin America and the Middle East & Africa are also expected to experience steady growth as healthcare accessibility continues to improve and awareness regarding chronic autoimmune diseases increases.

Competitive Landscape

The global psoriasis treatment market remains highly competitive, with established pharmaceutical companies continuously investing in research, clinical development, strategic partnerships, product launches, and acquisitions to strengthen their global market presence. Companies are increasingly focused on expanding biologic portfolios, developing biosimilars, introducing novel oral therapies, and advancing next-generation immunology platforms that improve efficacy, safety, and patient adherence. Innovation in cytokine inhibition, personalized medicine, and precision dermatology continues to reshape competitive dynamics. Leading players operating in the market include AbbVie Inc., Amgen Inc., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Services, Inc., LEO Pharma A/S, Merck & Co., Inc., Novartis AG, Boehringer Ingelheim Pharmaceuticals, Inc., Arcutis Biotherapeutics, Inc., Dermavant Sciences, Inc., TIEFENBACHER GROUP, UCB S.A., Bausch Health, Sun Pharmaceutical Industries Limited, and Akeso Biopharma Co., Ltd. Their continuous investments in product innovation and global commercialization strategies are expected to intensify market competition throughout the forecast period.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453